On January 8, 2024, Solid Biosciences, a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell 16,973,103 shares of common stock at a price of $5.53 per share and, in lieu of common stock, pre-funded warrants to purchase up to 2,712,478 shares of common stock at a price of $5.529 per pre-funded warrant. The aggregate gross proceeds from the offering are expected to be approximately $109 million.

The WilmerHale team advising Solid Biosciences in its private placement included Caroline Dotolo, Sarah Matchett and Connor McRory.